Pharma giant eyes emerging markets

DUBAI: Pfizer Inc, the world's largest drugmaker, is looking to conclude deals in emerging markets over "few months" to raise its share of a market estimated at about $80 billion, an executive said.

Pharmaceutical companies are increasingly turning their attention to developing nations as they face tougher conditions in more mature markets.

The drugmaker struck a $68 billion deal in January to acquire US rival Wyeth to help shore up profits and in May signed licensing agreements with two Indian-based companies as it seeks new growth opportunities in generics and emerging markets.